Turing Medical Launches New Brain Mapping and Targeting Solution at ASSFN Biannual Meeting
Turing Medical , the leader in precision targeting for neuromodulation therapies, today announced the launch of Bullsai, its new brain mapping and targeting solution, at the American Society for Stereotactic and Functional Neurosurgery (ASSFN) Biennial Meeting in Nashville, Tenn.
- Turing Medical , the leader in precision targeting for neuromodulation therapies, today announced the launch of Bullsai, its new brain mapping and targeting solution, at the American Society for Stereotactic and Functional Neurosurgery (ASSFN) Biennial Meeting in Nashville, Tenn.
- Pending FDA clearance, Bullsai is currently available for research use and marks a milestone in delivering precision brain mapping and targeting to the emerging field of neuromodulation therapy.
- However, existing coordinate-based targeting strategies fail to account for the considerable variability in brain structure and function between patients.
- Turing has developed an advanced MRI processing pipeline to identify neuroanatomical structures, white matter pathways, and functional brain networks to personalize targeting for individual patients.